SG11202009735QA - Bcl6 inhibitors - Google Patents
Bcl6 inhibitorsInfo
- Publication number
- SG11202009735QA SG11202009735QA SG11202009735QA SG11202009735QA SG11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA
- Authority
- SG
- Singapore
- Prior art keywords
- bcl6 inhibitors
- bcl6
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806132.5A GB201806132D0 (en) | 2018-04-13 | 2018-04-13 | Inhibitor coumpounds |
| GBGB1819136.1A GB201819136D0 (en) | 2018-11-23 | 2018-11-23 | Inhibitor compounds |
| PCT/GB2019/051058 WO2019197842A1 (en) | 2018-04-13 | 2019-04-12 | Bcl6 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009735QA true SG11202009735QA (en) | 2020-10-29 |
Family
ID=66240166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009735QA SG11202009735QA (en) | 2018-04-13 | 2019-04-12 | Bcl6 inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11512095B2 (es) |
| EP (2) | EP4201939A1 (es) |
| JP (2) | JP7493454B2 (es) |
| KR (1) | KR20200144109A (es) |
| CN (1) | CN112334475B (es) |
| AU (2) | AU2019253510B2 (es) |
| BR (1) | BR112020020832A2 (es) |
| CA (1) | CA3095371A1 (es) |
| DK (1) | DK3774817T3 (es) |
| ES (1) | ES2939776T3 (es) |
| HR (1) | HRP20230120T1 (es) |
| IL (2) | IL296734A (es) |
| MX (2) | MX2020010805A (es) |
| PT (1) | PT3774817T (es) |
| SG (1) | SG11202009735QA (es) |
| WO (1) | WO2019197842A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2939776T3 (es) * | 2018-04-13 | 2023-04-26 | Cancer Research Tech Ltd | Inhibidores de BCL6 |
| GB201909573D0 (en) | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
| GB201914860D0 (en) * | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| WO2021077010A1 (en) * | 2019-10-17 | 2021-04-22 | Arvinas Operations, Inc. | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| PE20240639A1 (es) | 2021-04-16 | 2024-04-04 | Arvinas Operations Inc | Moduladores de la proteolisis bcl6 y metodos de uso asociados |
| WO2023240038A1 (en) | 2022-06-06 | 2023-12-14 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
| WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| WO2024019995A1 (en) * | 2022-07-19 | 2024-01-25 | Dana-Farber Cancer Institute, Inc. | Quinoxalinedione and pyrido [2, 3-b]pyrazine-2, 3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof |
| WO2024193464A1 (zh) * | 2023-03-17 | 2024-09-26 | 西藏海思科制药有限公司 | 一种含氮三并环衍生物及其在医药上的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL144745A0 (en) | 1999-02-10 | 2002-06-30 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| MX2011004957A (es) * | 2008-11-11 | 2011-08-12 | Je Il Pharmaceutical Co Ltd | Nuevo derivado triciclico o las sales farmaceuticamente aceptables del mismo, metodo de preparacion del mismo, y composicion farmaceutica que contiene el mismo. |
| RU2015141360A (ru) | 2013-03-05 | 2017-04-10 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
| WO2014204859A2 (en) | 2013-06-17 | 2014-12-24 | Melnick Ari | Bcl6 inhibitors as anticancer agents |
| WO2018108704A1 (en) | 2016-12-13 | 2018-06-21 | Boehringer Ingelheim International Gmbh | New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors |
| WO2018215798A1 (en) * | 2017-05-26 | 2018-11-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| BR112019024830A2 (pt) | 2017-05-26 | 2020-06-09 | Cancer Research Tech Ltd | inibidores de bcl6 derivados de benzimidazolona |
| ES2939776T3 (es) * | 2018-04-13 | 2023-04-26 | Cancer Research Tech Ltd | Inhibidores de BCL6 |
-
2019
- 2019-04-12 ES ES19718834T patent/ES2939776T3/es active Active
- 2019-04-12 SG SG11202009735QA patent/SG11202009735QA/en unknown
- 2019-04-12 HR HRP20230120TT patent/HRP20230120T1/hr unknown
- 2019-04-12 MX MX2020010805A patent/MX2020010805A/es unknown
- 2019-04-12 BR BR112020020832-9A patent/BR112020020832A2/pt unknown
- 2019-04-12 EP EP22211485.2A patent/EP4201939A1/en active Pending
- 2019-04-12 KR KR1020207032149A patent/KR20200144109A/ko not_active Application Discontinuation
- 2019-04-12 WO PCT/GB2019/051058 patent/WO2019197842A1/en active Application Filing
- 2019-04-12 DK DK19718834.5T patent/DK3774817T3/da active
- 2019-04-12 JP JP2020555420A patent/JP7493454B2/ja active Active
- 2019-04-12 PT PT197188345T patent/PT3774817T/pt unknown
- 2019-04-12 US US17/046,650 patent/US11512095B2/en active Active
- 2019-04-12 EP EP19718834.5A patent/EP3774817B1/en active Active
- 2019-04-12 CN CN201980039513.4A patent/CN112334475B/zh active Active
- 2019-04-12 CA CA3095371A patent/CA3095371A1/en active Pending
- 2019-04-12 AU AU2019253510A patent/AU2019253510B2/en active Active
- 2019-04-12 IL IL296734A patent/IL296734A/en unknown
-
2020
- 2020-10-04 IL IL277778A patent/IL277778B2/en unknown
- 2020-10-12 MX MX2023004920A patent/MX2023004920A/es unknown
-
2022
- 2022-10-18 US US17/968,159 patent/US20230287003A1/en active Pending
-
2023
- 2023-11-09 AU AU2023263501A patent/AU2023263501A1/en active Pending
-
2024
- 2024-05-21 JP JP2024082277A patent/JP2024119835A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230287003A1 (en) | 2023-09-14 |
| AU2019253510B2 (en) | 2023-08-10 |
| JP2024119835A (ja) | 2024-09-03 |
| JP2021521165A (ja) | 2021-08-26 |
| IL296734A (en) | 2022-11-01 |
| EP3774817B1 (en) | 2022-12-07 |
| KR20200144109A (ko) | 2020-12-28 |
| CN112334475B (zh) | 2024-10-29 |
| EP4201939A1 (en) | 2023-06-28 |
| EP3774817A1 (en) | 2021-02-17 |
| JP7493454B2 (ja) | 2024-05-31 |
| CN112334475A (zh) | 2021-02-05 |
| AU2023263501A1 (en) | 2023-11-30 |
| IL277778B2 (en) | 2023-03-01 |
| IL277778A (en) | 2020-11-30 |
| BR112020020832A2 (pt) | 2021-01-19 |
| MX2023004920A (es) | 2023-05-16 |
| DK3774817T3 (da) | 2023-02-13 |
| AU2019253510A1 (en) | 2020-10-22 |
| US20210163497A1 (en) | 2021-06-03 |
| CA3095371A1 (en) | 2019-10-17 |
| US11512095B2 (en) | 2022-11-29 |
| HRP20230120T1 (hr) | 2023-06-09 |
| WO2019197842A1 (en) | 2019-10-17 |
| ES2939776T3 (es) | 2023-04-26 |
| IL277778B (en) | 2022-11-01 |
| MX2020010805A (es) | 2021-01-29 |
| PT3774817T (pt) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | kif18a inhibitors | |
| IL292643A (en) | ras inhibitors | |
| IL292642A (en) | ras inhibitors | |
| IL292644A (en) | ras inhibitors | |
| SG11202009933WA (en) | Bcl-2 INHIBITORS | |
| IL269196A (en) | New inhibitors | |
| IL277778B (en) | inhibitors of bcl6 | |
| IL276813A (en) | Arginase inhibitors | |
| EP3817736A4 (en) | PIKFYVE INHIBITORS | |
| ZA201907136B (en) | Ip6k inhibitors | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| ZA201808552B (en) | Novel b-lactamase inhibitors | |
| EP3600301A4 (en) | KDM4 INHIBITORS | |
| IL283309A (en) | rip1 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
| IL277806A (en) | Growth inhibitor | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| IL283112A (en) | LOX inhibitors | |
| GB201809295D0 (en) | Lox inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor |